EVAX earnings date and last-quarter result: next report 2026-08-13, last quarter in line, P/E -1.99. Updated 2026-07-23.
Evaxion Biotech (EVAX) Research Hub
Evaxion Biotech (EVAX) trades on NASDAQ, DK in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.08 USD (-18.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.99, market cap 0.02B. This hub links to the full technical, earnings and options research available for EVAX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DK |
| Last close | 3.08 USD (-18.09%) |
| 52-week range | 2.72 USD – 4.5 USD |
| Trend regime | Range |
| 14-day RSI | 48.6 (Neutral) |
| Trailing P/E | -1.99 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for EVAX
Covered Call on EVAX: how it works, illustrative setup around the real 3.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EVAX: how it works, illustrative setup around the real 3.08 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EVAX: how it works, illustrative setup around the real 3.08 USD price, max profit/loss, breakeven and when to use it. Educational.
EVAX technical analysis: range, last 3.08 USD, RSI 48.6, 52w range 2.72 USD–4.5 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is EVAX in?
Evaxion Biotech (EVAX) is classified under Healthcare (Biotechnology), listed on NASDAQ, DK.
Is EVAX in an uptrend or downtrend?
As of 2026-10-26, EVAX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EVAX's trailing P/E ratio?
EVAX's trailing P/E is -1.99, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does EVAX next report earnings?
EVAX is next scheduled to report earnings on 2026-08-13.